Breaking News, Financial News

Financial Report: Lilly

Cymbalta expiration begins to weigh down sales

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Lilly 4Q13 4Q Revenues: $5.8 billion (-2%) 4Q Earnings: $728 million (-12%) FY Revenues: $23.1 billion (+2%) FY Earnings: $4.7 billion (+15%) Comments: The U.S. patent for Cymbalta expired on Dec. 11, 2013, leading U.S. pharma revenues to fall 6% in 4Q13 to $3.0 billion. Cymbalta revenues dropped 38% in 4Q13 to $883 million, while sales in FY13 rose 2% to $5.1 billion. Zyprexa sales dropped 10% in 4Q13 to $348 million and fell 30% in FY13 to $1.2 billion. Humalog posted 19% growth in 4Q13 t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters